Delivery Order SPE2DB22D2211-SPE2DB25FSCWM
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,066.12 and an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,269.13 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $2,846.53 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg on August 28, 2025, with completion scheduled for August 29, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,679.97 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg, with an ultimate completion date of September 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $2,437.80 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on August 7, 2025, with completion scheduled for August 8, 2025. This non-competitive, firm fixed-price delivery order represents a single pharmaceutical transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $6,467.94 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100 count) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitive award, structured as a firm fixed-price delivery order with no set-aside designation, is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $6,292.03. The order, which is not set-aside for any disadvantaged business category, is scheduled for completion by August 13, 2025, and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $2,565.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $15,814.20 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 26, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCWMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Vyvanse 70 mg capsules (100-count units) valued at $3,496.33 with a firm fixed price structure. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026. The delivery order is scheduled for completion by August 15, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company supplies an extensive portfolio of pharmaceutical products and medical supplies to support military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. This delivery order for Vyvanse, a prescription medication used in treating attention deficit hyperactivity disorder, exemplifies the company's role in fulfilling diverse pharmaceutical requirements across multiple therapeutic domains for the Department of Defense medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 8/14/25 |